METTL1-mediated m7G hypomethylation promotes tsRNA biogenesis in prostate cancer [108], and m7G-modified tsRNA-LysTTT catalyzed by METTL1 enhances bladder cancer malignancy [109]. This evidence concerns the gene METTL1 and prostate carcinoma.